YU YAO BIOTECH

YU YAO BIOTECH was founded in 2020 as a high-tech enterprise driven by artificial intelligence and modern drug discovery technologies to lead small molecule drug discovery. Focusing on addressing significant unmet clinical needs and improving human health, the company is committed to the development and research of innovative drugs with proprietary intellectual property rights. Since its establishment, YU YAO BIOTECH has been building a world-leading innovative drug R&D platform, continuously delivering a competitive product pipeline with global impact. The company has successfully established three cutting-edge technological platforms globally: GPCR drug development, “Undruggable” target drug development, and AI-assisted drug discovery. Its robust portfolio includes eight innovative products under development, strategically targeting difficult-to-treat and recurrent solid tumors, hematological malignancies, neurodegenerative diseases, and autoimmune disorders.